Welcome to our dedicated page for Optimi Health news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Optimi Health Corp. (OPTHF) is a Health Canada-licensed manufacturer specializing in GMP-certified psychedelic substances for therapeutic research. This page provides investors and researchers with verified updates on the company’s regulatory progress, clinical partnerships, and production capabilities.
Access comprehensive coverage of Optimi Health’s developments including export agreements, compliance milestones, and research initiatives. Users will find press releases related to pharmaceutical-grade psilocybin production, MDMA formulation advancements, and international distribution partnerships across regulated markets.
Key updates focus on Health Canada licensing status, GMP manufacturing standards, clinical trial support, and strategic collaborations with global research organizations. All content is curated to meet investor needs for timely, accurate information in the evolving psychedelic pharmaceuticals sector.
Bookmark this page for streamlined access to Optimi Health’s official announcements. Check regularly for updates on regulatory approvals and advancements in psychedelic-assisted therapy research.
Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) has provided an update on its 20,000 sq. ft. production facility in Princeton, British Columbia. The project is currently three to four weeks behind schedule due to supply chain challenges, which the company considers acceptable in light of the global health crisis. The company is moving forward with construction for a Controlled Substance Dealers License and has been advised that the proposed security measures may meet Health Canada requirements. Progress on facility systems is ongoing, with most equipment expected on-site within a month.
Optimi Health Corp. announces the appointment of William J. Ciprick as CEO, effective September 7, 2021. With over 30 years of global experience in various industries, including leadership roles at BDC Advisory Services and Procter & Gamble, Ciprick aims to drive growth and commercialization of Optimi's functional mushroom products. He replaces Mike Stier, who will remain with the company as a director. Optimi focuses on the health and wellness sector and is nearing completion of a 20,000 square foot facility in Princeton, British Columbia.
Optimi Health Corp. announced preparations for a Q4 launch of online sales featuring a range of functional mushroom products, including capsules and a vegan protein formulation. Chief Marketing Officer Dane Stevens highlighted the company's goal of transforming into a revenue-generating entity, leveraging new revenues to spur value creation and fund ongoing initiatives. The initial sales will target the Canadian market with plans to enter the US market in 2022. Collaborations with marketing agencies aim to enhance consumer awareness and support the launch.
Optimi Health Corp. has engaged industry veteran John Simon to enhance its regulatory submissions and psychedelic research efforts. Simon brings extensive experience in regulatory affairs and has worked with FDA and Health Canada. His role is pivotal for Optimi's goal of conducting clinical trials on psilocybin-based formulations, meeting international standards, and securing intellectual property rights. The company aims to improve mental health through its innovative mushroom products and has received regulatory exemptions for research into psilocybin and psilocin.
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) has announced its inclusion in the first psychedelics Exchange Traded Fund (ETF), trading on the Neo Exchange since January 26, 2021. The ETF invests in companies involved in the psychedelics industry, with Optimi Health receiving a 1.74% weighting upon inclusion. Managed by Horizons ETF Management, the ETF aims to replicate the performance of the North American Psychedelics Index. CEO Mike Stier highlighted this inclusion as a significant milestone, enhancing visibility and investor confidence for Optimi's stakeholders.
Optimi Health Corp. has engaged Donohoe Advisory Associates LLC to assist in exploring strategies for a potential Nasdaq listing. Donohoe Advisory, founded by David A. Donohoe, Jr., consists of former Nasdaq staff and specializes in public company listings. CEO Mike Stier emphasized that this engagement marks significant progress towards achieving a senior market listing. Optimi is focused on developing a sophisticated mushroom brand, backed by research exemptions and licenses for Psilocybin and Psilocin, aiming for health and wellness markets.
Optimi Health Corp. (OTC: OPTHF) has announced its collaboration as a Core Spore Supporter with TheraPsil, a non-profit coalition advocating for patient access to psilocybin therapy in Canada. This partnership includes financial support aimed at increasing access to psilocybin-assisted psychotherapy, particularly for patients experiencing end-of-life distress. Since August 2020, TheraPsil has facilitated 31 patients to obtain legal exemptions for psilocybin therapy. Optimi is committed to developing a high-quality mushroom brand, focusing on psilocybin's medicinal benefits.
Optimi Health Corp. has successfully uplisted to the OTCQB exchange, retaining its ticker symbol OPTHF. This exchange is designed for developing companies, requiring compliance with financial reporting and management certification. The OTCQB enhances visibility for investors, potentially improving liquidity and future capital access. In addition to trading on OTCQB, Optimi shares remain listed on the Canadian Securities Exchange (OPTI) and the German Börse Frankfurt (FRA: 8BN). Optimi is focused on health and wellness through mushroom products and has obtained research exemptions for Psilocybin and Psilocin development.
Optimi Health Corp. has received approval from Health Canada to proceed with a submission for a Phase 1 study of psilocybin. This follows discussions with the IMPACT Clinical Trials Accelerator at the University of Calgary. The study aims to explore the safety and efficacy of psilocybin, a natural compound derived from mushrooms, for mental health treatments. The formal application is expected to be submitted shortly, with trials anticipated to commence in Q3 2021. Optimi retains full ownership of the psilocybin product and intellectual property rights.
Optimi Health Corp. (CSE: OPTI, OTC: OPTHF) has signed a non-exclusive agreement with Vitasave, a leading Canadian natural health company, for product distribution. Vitasave will feature Optimi's functional mushroom products in its retail locations and online. Optimi is focused on the health and wellness market and operates a vertically integrated model for mushroom cultivation, extraction, and distribution. The company is also pursuing a dealer’s license for Psilocybin and Psilocin under Canadian regulations.
